Tags

Type your tag names separated by a space and hit enter

Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study.
J Am Acad Dermatol 2004; 51(5):731-8JA

Abstract

BACKGROUND

Inverse psoriasis can be difficult to treat because of the high sensitivity of intertriginous areas to cutaneous side effects, such as irritation and striae. Pimecrolimus, a well-tolerated, nonatrophogenic, skin-selective inflammatory cytokine inhibitor, has been shown to be effective in the treatment of psoriasis when applied topically under occlusion.

OBJECTIVE

This study evaluated the efficacy and safety of pimecrolimus cream 1% versus vehicle twice a day in the treatment of inverse psoriasis. Methods This was a double-blind, randomized, vehicle-controlled study in 57 patients with moderate to severe inverse psoriasis. Patients were evaluated using Investigator's Global Assessment of overall severity, Target Area Score, and Patient Self-Assessment.

RESULTS

A significant between-group difference was observed early on, with 54% of the pimecrolimus group versus 21% of the vehicle group having an Investigator's Global Assessment score of 0 or 1 (clear or almost clear) at week 2 (P = .0169). By week 8, 71% of the pimecrolimus group had an Investigator's Global Assessment score of 0 or 1. Change from baseline in Target Area Score was -2.4 (pimecrolimus group) compared with -0.7 (vehicle) at day 3 (P < .0001). By week 8, 82% of patients using pimecrolimus scored their disease as well or completely controlled versus 41% of the vehicle group (P = .0007). Adverse events were similar between groups.

CONCLUSION

Pimecrolimus cream 1% is an effective treatment for inverse psoriasis with a rapid onset of action, and is safe and well-tolerated.

Authors+Show Affiliations

Mt Sinai School of Medicine, Department of Dermatology, New York, New York, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15523351

Citation

Gribetz, Carin, et al. "Pimecrolimus Cream 1% in the Treatment of Intertriginous Psoriasis: a Double-blind, Randomized Study." Journal of the American Academy of Dermatology, vol. 51, no. 5, 2004, pp. 731-8.
Gribetz C, Ling M, Lebwohl M, et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol. 2004;51(5):731-8.
Gribetz, C., Ling, M., Lebwohl, M., Pariser, D., Draelos, Z., Gottlieb, A. B., ... Menter, A. (2004). Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. Journal of the American Academy of Dermatology, 51(5), pp. 731-8.
Gribetz C, et al. Pimecrolimus Cream 1% in the Treatment of Intertriginous Psoriasis: a Double-blind, Randomized Study. J Am Acad Dermatol. 2004;51(5):731-8. PubMed PMID: 15523351.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. AU - Gribetz,Carin, AU - Ling,Mark, AU - Lebwohl,Mark, AU - Pariser,David, AU - Draelos,Zoe, AU - Gottlieb,Alice B, AU - Zaias,Nardo, AU - Chen,Diana M, AU - Parneix-Spake,Anne, AU - Hultsch,Thomas, AU - Menter,Alan, PY - 2004/11/4/pubmed PY - 2005/5/17/medline PY - 2004/11/4/entrez SP - 731 EP - 8 JF - Journal of the American Academy of Dermatology JO - J. Am. Acad. Dermatol. VL - 51 IS - 5 N2 - BACKGROUND: Inverse psoriasis can be difficult to treat because of the high sensitivity of intertriginous areas to cutaneous side effects, such as irritation and striae. Pimecrolimus, a well-tolerated, nonatrophogenic, skin-selective inflammatory cytokine inhibitor, has been shown to be effective in the treatment of psoriasis when applied topically under occlusion. OBJECTIVE: This study evaluated the efficacy and safety of pimecrolimus cream 1% versus vehicle twice a day in the treatment of inverse psoriasis. Methods This was a double-blind, randomized, vehicle-controlled study in 57 patients with moderate to severe inverse psoriasis. Patients were evaluated using Investigator's Global Assessment of overall severity, Target Area Score, and Patient Self-Assessment. RESULTS: A significant between-group difference was observed early on, with 54% of the pimecrolimus group versus 21% of the vehicle group having an Investigator's Global Assessment score of 0 or 1 (clear or almost clear) at week 2 (P = .0169). By week 8, 71% of the pimecrolimus group had an Investigator's Global Assessment score of 0 or 1. Change from baseline in Target Area Score was -2.4 (pimecrolimus group) compared with -0.7 (vehicle) at day 3 (P < .0001). By week 8, 82% of patients using pimecrolimus scored their disease as well or completely controlled versus 41% of the vehicle group (P = .0007). Adverse events were similar between groups. CONCLUSION: Pimecrolimus cream 1% is an effective treatment for inverse psoriasis with a rapid onset of action, and is safe and well-tolerated. SN - 1097-6787 UR - https://www.unboundmedicine.com/medline/citation/15523351/full_citation L2 - https://linkinghub.elsevier.com/retrieve/pii/S0190962204015786 DB - PRIME DP - Unbound Medicine ER -